

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Single Technology Appraisal**

**Topical tapinarof for treating mild to severe plaque psoriasis ID6712**

**Provisional Stakeholder List**

<b>Provisional Consultees</b>	<b>Provisional Commentators (no right to submit or appeal)</b>
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Organon Pharma (topical tapinarof)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Changing Faces</li> <li>• Gene People</li> <li>• Genetic Alliance UK</li> <li>• Let's Face It</li> <li>• Psoriasis and Psoriatic Arthritis Alliance (PAPAA)</li> <li>• Psoriasis Association</li> <li>• Psoriasis Help Organisation</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> </ul> <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Genetic Nurses &amp; Counsellors</li> <li>• British Association of Dermatologists</li> <li>• British Dermatological Nursing Group</li> <li>• British Geriatrics Society</li> <li>• British Society for Cutaneous Allergy</li> <li>• British Society for Genetic Medicine</li> <li>• Primary Care Dermatology Society</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• St John's Institute of Dermatology</li> <li>• UK Clinical Pharmacy Association</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health - Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Confederation</li> <li>• NHS Wales Joint Commissioning Committee</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Government</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• AbbVie (adalimumab, risankizumab)</li> <li>• Almirall (dimethyl fumarate, tildrakizumab)</li> <li>• AmaroX (apremilast)</li> <li>• Amgen (adalimumab, apremilast, ustekinumab)</li> <li>• Aristo Pharma (apremilast)</li> <li>• Biogen (adalimumab, etanercept, infliximab)</li> <li>• Bristol Myers Squibb (deucravacitinib)</li> <li>• Celix Pharma (apremilast)</li> <li>• Celltrion Healthcare (adalimumab, infliximab, ustekinumab)</li> <li>• Cipla (methotrexate)</li> <li>• Dexcel Pharma (ciclosporin)</li> <li>• Eli Lilly (ixekizumab)</li> </ul>

Provisional stakeholder list for the evaluation of topical tapinarof for treating mild to severe plaque psoriasis ID6712

Issue date: June 2026

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
	<ul style="list-style-type: none"> <li>• Esteve Pharmaceuticals (methotrexate)</li> <li>• Fresenius Kabi (adalimumab, ustekinumab)</li> <li>• Genus Pharmaceuticals (acitretin, apremilast, ustekinumab)</li> <li>• Hospira (methotrexate)</li> <li>• Janssen-Cilag a Johnson &amp; Johnson Company(guselkumab, infliximab, ustekinumab)</li> <li>• Johnson &amp; Johnson (icotrokinra)</li> <li>• Krka UK (apremilast)</li> <li>• Leo Laboratories (brodalumab)</li> <li>• Medac (methotrexate)</li> <li>• Morningside Healthcare (acitretin, ciclosporin, methotrexate)</li> <li>• Novartis Pharmaceuticals UK (ciclosporin, secukinumab)</li> <li>• Orion Pharma (methotrexate)</li> <li>• Pfizer (etanercept, infliximab)</li> <li>• Rosemont Pharmaceuticals (methotrexate)</li> <li>• Samsung Bioepis (ustekinumab)</li> <li>• Sandoz (adalimumab, etanercept, infliximab, methotrexate)</li> <li>• Teva UK (acitretin)</li> <li>• UCB Pharma (bimekizumab, certolizumab pegol)</li> <li>• Viartis (ciclosporin)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• British Skin Foundation</li> <li>• Centre of Evidence-based Dermatology, University of Nottingham</li> <li>• Cochrane Skin Group</li> <li>• Dermatrust</li> <li>• Genomics England</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• Public Health Wales</li> <li>• UK Health Security Agency</li> </ul>

Provisional stakeholder list for the evaluation of topical tapinarof for treating mild to severe plaque psoriasis ID6712

Issue date: June 2026

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

### **Definitions:**

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.